TNW | Investors-funding
bit.bio raises $25M Series D as demand for its human cell models grows
Cambridge biotech bit.bio has raised $25m from M&G and Abcam founder Jonathan Milner to bring more lab-grown human cell types to market.
By TNW | Investors-funding
Excerpt shared by Lazyfounder
·Excerpt
Cambridge-based biotech company bit.bio has raised $25M in a Series D round, ten months after securing its previous investment.
The company announced the new funding on Wednesday, with backing from existing investor M&G Investments and Dr Jonathan Milner, founder and former chief executive of research tools company Abcam.
bit.bio did not disclose a lead investor or its valuation…
Courtesy
This story was originally published by TNW | Investors-funding. All rights belong to the original publisher.
Read the original on thenextweb.com ↗